Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus-Reference-Cited by-同舟云学术

Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus

Published:2020-04 Issue:4 Volume:50 Page:512-523
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Tsuji Shohei¹,Uchida Yoshihito¹^ORCID,Uemura Hayato¹,Kouyama Jun‐Ichi¹,Naiki Kayoko¹,Nakao Masamitsu¹^ORCID,Motoya Daisuke¹,Sugawara Kayoko¹,Nakayama Nobuaki¹,Imai Yukinori¹,Tomiya Tomoaki¹,Mochida Satoshi¹

Affiliation:

1. Department of Gastroenterology & Hepatology, Faculty of MedicineSaitama Medical University Moroyama Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13471

Reference26 articles.

1. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

2. A Novel Simple Assay System to Quantify the Percent HCV-RNA Levels of NS5A Y93H Mutant Strains and Y93 Wild-Type Strains Relative to the Total HCV-RNA Levels to Determine the Indication for Antiviral Therapy with NS5A Inhibitors

3. Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing